Biocon Malaysia arm gets UK regulator approval for Semglee fill finish unit - CNBC TV18

Reported by CNBC-TV18 Markets, not nibnow. We are not the publisher of this story, only the source is.

No additional analysis available for this story yet.

WHAT HAPPENED

Earlier this month, Biocon MD and CEO Shreehas P Tambe told CNBC-TV18 that the company's insulin business can reach the $1 billion revenue mark soon. It i seeing strong demand for insulin and traction for newer products such as aflibercept supporting growth.

Text size

READ IN YOUR LENS

UPSCMarketsFounder

Read full article at CNBC-TV18 Markets